يعرض 1 - 10 نتائج من 27 نتيجة بحث عن '"Daniel F Alvarez"', وقت الاستعلام: 1.22s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis

    المؤلفون: Jonathan Kay, Muhammad Rehman, Noriko Iikuni, Daniel F Alvarez, Amy E Bock, Wuyan Zhang

    المصدر: RMD Open, Vol 8, Iss 2 (2022)

    مصطلحات موضوعية: Medicine

    وصف الملف: electronic resource

    Relation: https://rmdopen.bmj.com/content/8/2/e002423.full; https://doaj.org/toc/2056-5933

    URL الوصول: https://doaj.org/article/47d8bc8df4e64e589a693cd1f20f04d6

    Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

    المؤلفون: Rieke Alten, Carol Cronenberger, Daniel F Alvarez, Amy E Bock, Ivana Vranic, Wuyan Zhang

    المصدر: RMD Open, Vol 7, Iss 2 (2021)

    مصطلحات موضوعية: Medicine

    وصف الملف: electronic resource

    Relation: https://rmdopen.bmj.com/content/7/2/e001578.full; https://doaj.org/toc/2056-5933

    URL الوصول: https://doaj.org/article/7b89df7d1f944a94a3f3b1c2fa434ccb

    Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Prevalencia de enfermedades hepáticas en una población rural de alta montaña: estudio clínico, bioquímico y ecográfico

    المؤلفون: Sonia M Soria, Susana L Katz, Daniel F Alvarez, Roberto R Rodríguez, María G González, Pablo J D'Angelo, Pedro A Bulacio, Marcela I Sixto, Gustavo J Abdelnur, María E Garay, Ana M Bianchi, María I Leguina, María A Véliz, Federico G Villamil

    المصدر: Acta Gastroenterológica Latinoamericana, Vol 36, Iss 4, Pp 174-181 (2006)

    مصطلحات موضوعية: Diseases of the digestive system. Gastroenterology, RC799-869, Medicine

    وصف الملف: electronic resource

    Relation: http://www.redalyc.org/articulo.oa?id=199317400004; https://doaj.org/toc/0300-9033

    URL الوصول: https://doaj.org/article/880effa8f7734242925a6235cacc107e

    أضف إلى المفضلة
  4. 4
    A Comparative Study Assessing Multiple Switching between the Biosimilar Adalimumab PF-06410293 and Reference Adalimumab in Active Rheumatoid Arthritis—A Randomised Clinical Trial

    المؤلفون: Roy Fleischmann, Wassim Saikali, Sharad Lakhanpal, Daniel F. Alvarez, Donna S. Cox, Claudia Ana Ianos, Wuyan Zhang, Carol Cronenberger, Karen Wang

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::414b567e8543ac27c35a839fcb389fa8
    https://doi.org/10.2139/ssrn.4337374

    أضف إلى المفضلة
  5. 5
    Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?

    المؤلفون: Beverly Ingram, Laurent Peyrin-Biroulet, Markus Mueller, Noriko Iikuni, Eduardo Mysler, Silvio Danese, Valderílio Feijó Azevedo, Daniel F. Alvarez

    المصدر: Drugs

    مصطلحات موضوعية: Biological Products, Drug Substitution, business.industry, Decision Making, Internet privacy, Context (language use), Biosimilar, Review Article, Disease, law.invention, Clinical trial, Tolerability, Randomized controlled trial, Innovator, law, Animals, Humans, Medicine, Pharmacology (medical), Practice Patterns, Physicians', Medical prescription, business, Biosimilar Pharmaceuticals, Randomized Controlled Trials as Topic

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d55d7f5789334236628f824294c28741
    https://doi.org/10.1007/s40265-021-01610-1

    Find this article in full text from Springer Verlag. Find this article in full text from ProQuest
    أضف إلى المفضلة
  6. 6
    Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

    المؤلفون: Roy Fleischmann, Wuyan Zhang, Daniel F. Alvarez, Amy E. Bock, Ivana Vranic, Carol Cronenberger, Rieke Alten

    المصدر: Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-11 (2021)
    Arthritis Research & Therapy

    مصطلحات موضوعية: medicine.medical_specialty, Diseases of the musculoskeletal system, Arthritis, Rheumatoid, Double-Blind Method, Long-term, Internal medicine, medicine, Clinical endpoint, Adalimumab, Humans, media_common.cataloged_instance, European union, Rheumatoid arthritis, Adverse effect, Biosimilar Pharmaceuticals, Adalimumab-afzb, media_common, business.industry, Incidence (epidemiology), Biosimilar, Switch, medicine.disease, Rheumatology, Clinical trial, Treatment Outcome, RC925-935, Antirheumatic Agents, PF-06410293, Safety, business, human activities, Research Article, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a59b0f403e005dfc8a3d0a4d6c649485
    https://doaj.org/article/0ee2953ecc944c48b52581e98907ed2d

    Find this article in full text from Springer Verlag. Find this article in full text from ProQuest
    أضف إلى المفضلة
  7. 7
    Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects

    المؤلفون: Daniel F. Alvarez, Amy E. Bock, Carol Cronenberger, Donna S. Cox

    المصدر: Clinical Pharmacology in Drug Development

    مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Injections, Subcutaneous, Urology, Pharmaceutical Science, Original Manuscript, Bioequivalence, 030226 pharmacology & pharmacy, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Adalimumab, medicine, Distribution (pharmacology), Humans, Pharmacology (medical), Dosing, Adverse effect, Biosimilar Pharmaceuticals, bioequivalence, business.industry, Syringes, PF‐06410293, Articles, Middle Aged, Confidence interval, Healthy Volunteers, Injection Site Reaction, Tolerability, 030220 oncology & carcinogenesis, Female, business, pharmacokinetics, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75b9a3db92320f28eedc549db2b87384
    http://europepmc.org/articles/PMC8518774

    View record at Wiley
    أضف إلى المفضلة
  8. 8
    Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?

    المؤلفون: John Orazem, Daniel F. Alvarez, Gertjan Wolbink, Jonathan Kay, Carol Cronenberger

    المصدر: Biodrugs

    مصطلحات موضوعية: Review Article, Interchangeability, Food and drug administration, 03 medical and health sciences, 0302 clinical medicine, Humans, Medicine, Pharmacology (medical), Clinical efficacy, Product (category theory), Biosimilar Pharmaceuticals, Drug Approval, 030203 arthritis & rheumatology, Pharmacology, United States Food and Drug Administration, business.industry, Biosimilar, General Medicine, United States, Reference product, Risk analysis (engineering), Clinical evidence, 030220 oncology & carcinogenesis, Pharmacodynamics, business, Biotechnology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34c1c1cc478574e6fd8c2d4f482752a0
    https://doi.org/10.1007/s40259-020-00446-7

    Find this article in full text from Springer Verlag. Find this article in full text from ProQuest
    أضف إلى المفضلة
  9. 9
    A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing

    المؤلفون: Kai H. Liao, Donghua Yin, Constantino Kantaridis, Daniel F. Alvarez, K. Lea Sewell, Chandrasekhar Udata, Xu Meng

    المصدر: British Journal of Clinical Pharmacology

    مصطلحات موضوعية: Drug, media_common.quotation_subject, Population, immunogenicity, Bioequivalence, Pharmacology, 030226 pharmacology & pharmacy, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Similarity (network science), Pharmacokinetics, Humans, Medicine, Pharmacology (medical), 030212 general & internal medicine, education, Biosimilar Pharmaceuticals, media_common, education.field_of_study, business.industry, Immunogenicity, Adalimumab, Biosimilar, Original Articles, Disposition, Pharmaceutical Preparations, Therapeutic Equivalency, Original Article, biosimilar, business, pharmacokinetics

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24a25fd3450a8c6f1c4f56fc6e4dc06a
    https://doi.org/10.1111/bcp.14312

    View record at Wiley
    أضف إلى المفضلة
  10. 10
    Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay

    المؤلفون: Merel J l'Ami, Gerrit Jan Wolbink, Pleuni Ooijevaar-de Heer, Catherine H. Smith, Daniel F. Alvarez, M. Hart, M. T. Nurmohamed, Ronald F van Vollenhoven, Theo Rispens, Maarten Boers, Karien Bloem, Lea C. Berkhout, J. Ruwaard

    المساهمون: Rheumatology, ACS - Atherosclerosis & ischemic syndromes, AII - Inflammatory diseases, Epidemiology and Data Science, APH - Methodology, Graduate School, Clinical Immunology and Rheumatology, AMS - Ageing & Morbidty, Landsteiner Laboratory

    المصدر: Berkhout, L C, L'Ami, M J, Ruwaard, J, Hart, M H, Ooijevaar-De Heer, P, Bloem, K, Nurmohamed, M T, Van Vollenhoven, R F, Boers, M, Alvarez, D F, Smith, C H, Wolbink, G J & Rispens, T 2019, ' Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay ', Science Translational Medicine, vol. 11, no. 477, aat3356 . https://doi.org/10.1126/scitranslmed.aat3356
    Berkhout, L C, l'Ami, M J, Ruwaard, J, Hart, M H, Ooijevaar-de Heer, P, Bloem, K, Nurmohamed, M T, van Vollenhoven, R F, Boers, M, Alvarez, D F, Smith, C H, Wolbink, G J & Rispens, T 2019, ' Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay ', Science Translational Medicine, vol. 11, no. 477, aat3356 . https://doi.org/10.1126/scitranslmed.aat3356
    Science Translational Medicine, 11(477):aat3356. American Association for the Advancement of Science
    Science translational medicine, 11(477):aat3356. American Association for the Advancement of Science

    مصطلحات موضوعية: 0301 basic medicine, Male, musculoskeletal diseases, medicine.medical_specialty, medicine.drug_class, medicine.medical_treatment, Arthritis, Enzyme-Linked Immunosorbent Assay, Monoclonal antibody, Gastroenterology, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, Drug tolerance, Internal medicine, medicine, Adalimumab, Humans, skin and connective tissue diseases, 030203 arthritis & rheumatology, business.industry, Tumor Necrosis Factor-alpha, General Medicine, Drug Tolerance, Middle Aged, medicine.disease, Healthy Volunteers, humanities, TNF inhibitor, 030104 developmental biology, Withholding Treatment, Rheumatoid arthritis, Methotrexate, Tumor necrosis factor alpha, Biological Assay, Female, business, medicine.drug

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6426a29863a1d7a214e3f025a47767bc
    https://kclpure.kcl.ac.uk/ws/files/108251142/aat3356_ArticleContent_v6.pdf

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء